11kg on GLP-1s: what the weight loss numbers actually mean

What's this video probably claiming?

Based on the caption and hashtag cluster, @missectc is sharing a personal weight loss result of 11 kilograms, likely attributed to a GLP-1 receptor agonist. The #v2pens hashtag is a notable signal here. That tag is widely associated with compounded semaglutide or tirzepatide products circulating in the peptide community, not FDA-approved brand-name medications like Wegovy or Zepbound. The #peptidecommunity hashtag reinforces this. So the implied claim appears to be: I used a GLP-1 product (possibly compounded), lost 11kg, and this is a result others can expect. Creators in this space often frame their personal result as a template. That framing, however well-intentioned, glosses over the clinical reality that individual response to GLP-1 therapy varies substantially based on dose, duration, baseline metabolic health, diet, and which specific agent is being used.

What does the science actually show?

The clinical trial data on GLP-1 receptor agonists is genuinely impressive, but the numbers come with important context. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg weekly produced mean weight loss of 14.9% of body weight over 68 weeks in people with obesity. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced up to 20.9% mean body weight reduction over 72 weeks. Eleven kilograms of weight loss is plausible within those ranges, especially at lower body weights or earlier in treatment. But these results were achieved under controlled conditions, with behavioral intervention components, and at maximum approved doses. Real-world outcomes from registry data and observational studies tend to run 30 to 40 percent lower than trial outcomes, per analysis from Ghusn et al. (2022, Obesity Pillars). The 11kg figure is not unrealistic, but context around timeline and dose is everything.

Where does the social media noise diverge from clinical reality?

The peptide community on TikTok treats GLP-1 products as largely interchangeable, which is where things get clinically messy. Compounded semaglutide is not the same product as Wegovy or Ozempic. The FDA has stated explicitly that compounded drugs are not FDA-approved and have not been evaluated for safety, efficacy, or manufacturing quality in the same way. There have been documented adverse events from compounded GLP-1 products, including dosing errors linked to the use of semaglutide salt forms rather than the base form used in approved products. The #v2pens tag suggests this video may involve a compounded product, which cannot be assumed equivalent to the studied medication. Additionally, TikTok weight loss content systematically underreports side effect burden. In STEP 1, over 74% of participants experienced gastrointestinal side effects. That part rarely makes the show reel.

What should you actually know?

GLP-1 receptor agonists are among the most effective pharmacological tools for weight management currently available. The evidence base is real and substantial. But personal results shared on TikTok, even genuine ones, are not clinical guidance. Eleven kilograms of weight loss is a meaningful outcome, and it may well be legitimate. What you cannot know from a short-form video: what product was used, at what dose, over what time period, with what dietary changes, and whether any side effects occurred. If you are considering a GLP-1 medication, the conversation belongs with a licensed clinician who can review your metabolic health, contraindications (GLP-1s are contraindicated in personal or family history of medullary thyroid carcinoma), and whether a compounded or brand-name option is appropriate for your situation. Weight loss content on TikTok is not a substitute for that conversation.